Percutaneous Nephrolithotomy Market Size & Share 2025 - 2034

Percutaneous Nephrolithotomy Market Size

The global percutaneous nephrolithotomy market was valued at USD 1.2 billion in 2024. The market is expected to reach from USD 1.3 billion in 2025 to USD 2.3 billion in 2034, growing at a CAGR of 6.8% during the forecast period, according to the latest report published by Global Market Insights Inc.

The high market growth is attributed to the rising prevalence of kidney stones, growing preference for minimally invasive procedures, technological advancements in PCNL devices, and increasing healthcare expenditure and access to advanced care, among other contributing factors.
 

Percutaneous nephrolithotomy (PCNL) is a minimally invasive surgical operation that helps in the removal of large or complicated kidney stones that are not amenable to extracorporeal shockwave lithotripsy or ureteroscopy. The method comprises making a small cut in the patient’s back to obtain direct access to the kidney with a nephroscope. In this way, any part can be broken down and removed with a very high success rate and the least possible damage to the tissue and a short recovery time.
 

The leading players in the percutaneous nephrolithotomy market are OLYMPUS, Boston Scientific, KARL STORZ, Richard Wolf, and Dornier MedTech. These firms maintain their competitive advantage through constant product innovation, worldwide market presence, and considerable investments in research and development.
 

The market has increased from USD 1 billion in 2021 and reached USD 1.1 billion in 2023, with the historic growth rate of 5.3%. The market growth was driven by the rising prevalence of urolithiasis, increasing adoption of minimally invasive stone removal procedures, advancements in lithotripsy and nephroscope technologies, and expanding healthcare access in emerging economies.
 

Moreover, the global prevalence of kidney stones continues to rise due to dietary changes, obesity, and dehydration associated with sedentary lifestyles. For instance, according to the World Health Organization (WHO), in 2022, 1 in 8 people worldwide were living with obesity. The National Institutes of Health (NIH) also reported in 2022 that kidney stone prevalence increased by 18% in developed countries between 2021 and 2022.
 

With recurrence rates as high as 50% within five years, many patients require repeated interventions. As a result, the American Urological Association (AUA) reported in its 2023 guidelines that the number of Percutaneous Nephrolithotomy (PCNL) procedures increased by 25% between 2021 and 2023, solidifying PCNL as the preferred treatment for large kidney stones.
 

Furthermore, the rising healthcare spending in developing regions enables greater access to urology centres equipped for PCNL. Government initiatives to improve surgical infrastructure support the availability of stone removal services. This widens patient reach and increases procedure volumes.
 

Percutaneous Nephrolithotomy Market Trends

The market is growing considerably with the shift toward miniaturized PCNL techniques, integration of laser lithotripsy, growing use of image-guided and robotic-assisted PCNL, rise of day-care and tubeless PCNL procedures, and increasing focus on radiation-free procedures, among other factors collectively driving industry growth.
 

• High-power holmium:YAG lasers and thulium fiber lasers are increasingly used during PCNL to improve stone fragmentation efficiency. Laser integration offers better precision with lower thermal damage compared to traditional pneumatic lithotripsy. This trend is enhancing procedural success rates and reducing operative times.
   
• In addition, the adoption of advanced imaging modalities such as real-time ultrasound, 3D fluoroscopy, and CT-navigation is improving the safety and accuracy of renal access. Robotic-assisted PCNL is also emerging, enhancing scope maneuverability and reducing surgeon fatigue. These innovations are making PCNL safer and more standardized.
   
• Moreover, surgeons are reducing dependency on fluoroscopy due to rising concerns over radiation exposure to patients and operating teams. Ultrasound-guided PCNL is becoming more common as it offers real-time visualization without radiation risks. This trend aligns with global radiation safety initiatives in urology, thereby sustaining market growth.
   

Percutaneous Nephrolithotomy Market Analysis

Based on the product type, the percutaneous nephrolithotomy market is segmented into nephroscopes, lithotripsy systems, access systems, and other product types. The nephroscopes segment has asserted its dominance in the market by securing a significant market share of 37.8% in 2024 owing to its essential role in PCNL procedures, growing adoption of miniaturized and digital nephroscopes, and continuous product innovations that enhance surgical precision and visualization. The segment is expected to exceed USD 837.9 million by 2034, growing at a CAGR of 6.4% during the forecast period.
 

On the other hand, the access systems segment is expected to grow with a CAGR of 7.4%. The growth of this segment is driven by the rising adoption of mini-PCNL techniques, increasing use of disposable access kits to reduce infection risk, and continuous improvements in dilators and sheaths that enhance procedural safety and efficiency.
 

• The nephroscopes segment continues to dominate the market. The global burden of urolithiasis is growing due to lifestyle factors such as obesity, dehydration, and high-sodium diets. As the number of patients requiring PCNL rises, the demand for nephroscopes used in stone visualization and removal increases proportionally. This makes nephroscopes a critical component in stone management procedures.
   
• Additionally, the market is witnessing continuous innovation with the development of digital nephroscopes, high-definition visualization systems, and flexible nephroscopes. Enhanced optical clarity, slimmer profiles, and integrated irrigation channels improve surgical outcomes. These advancements are driving surgeon preference and procedural efficiency.
   
• The lithotripsy systems segment held a revenue of USD 386.4 million in 2024, with projections indicating a steady expansion at 7.1% CAGR from 2025 to 2034. The segmental growth is driven by the increasing demand for efficient stone fragmentation technologies and the growing adoption of high-powered holmium and thulium fiber lasers that improve stone clearance rates during PCNL. Additionally, advancements in laser miniaturization and compatibility with flexible scopes are expanding their use in complex and minimally invasive stone procedures.
   
• The access systems segment accounted for significant revenue in 2024, with projections indicating a steady expansion at 7.4% CAGR from 2025 to 2034. The segment is driven by the rising number of PCNL procedures requiring reliable renal tract creation and the growing preference for image-guided access solutions that improve procedural accuracy. Additionally, technological advancements in safety sheaths and balloon dilators are reducing operative time and complication risks, boosting adoption across urology centres.
   

Based on procedure type, the percutaneous nephrolithotomy market is segmented into standard PCNL, mini-PCNL, and micro-PCNL. The standard PCNL segment dominated the market in 2024, accounting for USD 690.4 million and is anticipated to grow at a CAGR of 6.7% during the forecast period.
 

• Standard PCNL remains the main method of choice for the removal of kidney stones measuring more than 2 cm and staghorn stones. It achieves a higher rate of stone clearance in comparison with ESWL and URS. Its clinical effectiveness is the main reason for its continued use in both developed and emerging markets.
   
• Moreover, the standard PCNL offers the highest stone-free rates of 85-95% after one single session. Its capacity to handle complex stone burdens with less need for pretreatments makes it a clinically and economically viable option. The short and efficient procedure is the main reason why it is still in use at high volume urology centres.
   
• The mini-PCNL segment accounted for significant revenue in 2024 and is anticipated to grow at a CAGR of 7.2% over the forecast period. The growth of the segment is driven by increasing clinical preference for reduced tissue trauma and lower postoperative pain, making it suitable for moderate-sized renal stones. Its expanding use in outpatient and day-care surgical settings further accelerates demand.
   
• The micro-PCNL segment held a revenue of USD 153.6 million in 2024, with projections indicating a steady expansion at 6.2% CAGR from 2025 to 2034. The segment is driven by its suitability for pediatric and small renal stone cases, offering ultra-minimally invasive access with minimal renal parenchymal damage. Growing surgeon adoption for precise calyceal access in complex anatomies is further supporting its uptake.
   

Based on patient, the percutaneous nephrolithotomy market is segmented into adult and pediatric. The adult segment dominated the market in 2024, accounting for USD 1 billion and is anticipated to grow at a CAGR of 6.6% during the forecast period.
 

• The highest prevalence of nephrolithiasis has been observed in adults between 30–60 years of age, which is mainly associated with long working hours, dehydration, and unhealthy dietary patterns. Due to busy lifestyles, the diagnosis is often delayed, thus resulting in larger stones that need to be removed by PCNL. This makes adults the largest group who perform PCNL procedures worldwide.
   
• Further, growing rates of obesity, metabolic syndrome, diabetes, and high-protein diets among adults significantly increase the risk of calcium oxalate and uric acid stones. Alcohol consumption, smoking, and low water intake further worsen stone recurrence. These lifestyle trends directly increase procedure demand in the adult population.
   
• The pediatric segment accounted for significant revenue in 2024 and is anticipated to grow at a CAGR of 7.9% over the forecast period. Pediatric PCNL demand is rising due to increasing incidence of childhood urolithiasis driven by obesity and metabolic disorders. Additionally, improved availability of child-specific miniaturized instruments and safer anaesthesia protocols is supporting higher adoption in pediatric urology centres.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the percutaneous nephrolithotomy market is classified into hospitals, ambulatory surgery centers, and other end users. The hospitals segment dominated the market with a revenue share of 63.5% in 2024 and is expected to reach USD 1.4 billion within the forecast period.
 

• Hospitals are equipped with high-end imaging systems (fluoroscopy, CT, ultrasound), modular operating rooms, and sterilization facilities essential for PCNL. These setups support complex stone surgeries requiring precision and safety. As PCNL is resource-intensive, hospitals remain the primary care setting.
   
• In addition, hospitals employ board-certified urologists along with anesthesiologists, radiologists, and surgical nurses who manage PCNL procedures efficiently. Complex cases, including bilateral stones or renal anomalies, require coordinated care only hospitals can provide. This specialized workforce ensures consistent patient inflow.
   
• The ambulatory surgery centers segment held a revenue of USD 328.8 million in 2024, with projections indicating a steady expansion at 7.3% CAGR from 2025 to 2034. Owing to the shift toward cost-efficient outpatient urological care and reduced hospital stay preferences among patients. Advancements in mini-PCNL techniques and faster recovery protocols enable safe same-day discharges, boosting ASC adoption.

North America Percutaneous Nephrolithotomy Market

North America dominated the market with the highest market share of 39.8% in 2024.
 

• The U.S. percutaneous nephrolithotomy market was valued at USD 394.6 million and USD 412.3 million in 2021 and 2022, respectively. The market size reached USD 450.8 million in 2024, growing from USD 431 million in 2023, and is anticipated to grow at a CAGR of 6% between 2025 to 2034.
   
• North America has one of the highest kidney stone prevalence rates globally (10–12% of the population), driven by high obesity rates, excessive sodium intake, and sedentary lifestyles. Dietary habits rich in animal protein and processed foods increase stone formation. This directly drives a strong demand for PCNL procedures.
   
• Furthermore, the U.S. and Canada have a well-established network of high-volume urology centers equipped for complex stone surgeries. Hospitals and specialty centers increasingly adopt modern PCNL technologies such as suction-assisted lithotripsy and digital nephroscopes. This advanced infrastructure accelerates procedural adoption in the region.
   

Europe Percutaneous Nephrolithotomy Market

Europe market accounted for USD 396.8 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• In Europe, countries adhere to uniform clinical standards that are regulated and provided by the European Association of Urology (EAU). The guidelines indicate that PCNL should be used as the primary method in the case of stones >2 cm and complicated staghorn calculi. As a result, this is the procedure that is consistently demanded in hospitals in Germany, Italy, France, and the U.K.
   
• Many European healthcare systems promote the adoption of minimally invasive surgical techniques to reduce hospital stays and healthcare costs. PCNL aligns with this healthcare efficiency model, leading to higher procedural preference in state-funded hospitals in Germany, Sweden, and the Netherlands.
   

Asia Pacific Percutaneous Nephrolithotomy Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 8.2% during the analysis timeframe.
 

• Asia-Pacific includes countries such as India, China, and Southeast Asia which are the most affected regions by kidney stones incidences due to the hot weather and lack of proper hydration. A majority of the population is developing complex renal calculi that necessitate surgical removal. As a result, there is a high and steady demand for PCNL procedures.
   
• Developing economies like India, China, and Indonesia are investing heavily in tertiary care hospitals and urology departments. Expansion of surgical capacity and equipment procurement supports large-scale adoption of PCNL. Government-backed healthcare reforms are accelerating access to advanced stone management.
   

Latin America Percutaneous Nephrolithotomy Market

The Latin America market is experiencing robust growth over the analysis timeframe.
 

• The Latin America market is driven by a growing burden of untreated kidney stone cases due to limited early diagnosis and delayed treatment, leading to complex stones that require PCNL intervention. Rising healthcare modernization in countries such as Brazil, Mexico, Chile, and Argentina is expanding access to endourology procedures.
   
• Increasing urbanization and dehydration-related stone formation in tropical climates further drive procedure demand. Medical training collaborations with U.S. and European urologists are improving surgical skills and boosting PCNL adoption in regional hospitals.
   
• Additionally, public and private investments in hospital infrastructure, along with better availability of fluoroscopy and nephroscopes, are enabling wider use of PCNL across Latin America.
   

Middle East & Africa Percutaneous Nephrolithotomy Market

The Middle East & Africa (MEA) market is experiencing robust growth over the analysis timeframe.
 

• The regional growth is driven by a high prevalence of kidney stones due to extreme temperatures, chronic dehydration, and high mineral content in drinking water across Gulf and North African countries. Increasing investments in healthcare infrastructure in Saudi Arabia, UAE, and South Africa are expanding access to advanced urology procedures.
   
• Government-led expansion of tertiary care hospitals and urology centers is improving surgical capacity. Growing health insurance penetration and the rise of private hospital chains are also increasing affordability of PCNL. Additionally, international surgeon training programs and partnerships support procedure adoption across the region.
   

Percutaneous Nephrolithotomy Market Share

The global market is moderately consolidated, with global medtech leaders and specialized urology device manufacturers dominating the segment. Key players include OLYMPUS, Boston Scientific, KARL STORZ, Richard Wolf, and Dornier MedTech, collectively accounting for ~58% of the total market share.
 

These companies maintain strong market positions through robust product portfolios in nephroscopes, lithotripsy systems, access kits, and PCNL visualization technologies. Strategic emphasis on product innovation, procedural efficiency, and clinical safety has led to continuous upgrades in digital endoscopy, miniaturized PCNL instruments, and high-powered laser lithotripsy solutions.
 

In addition, the market is witnessing increasing participation from emerging players such as ELMED, PolyDiagnost, EMS Electro Medical Systems, and Advin Health Care, particularly in cost-sensitive regions across Asia-Pacific and Latin America.
 

Strategic collaborations with hospitals, investments in R&D for mini-PCNL and single-use nephroscopes, and partnerships with distributors for global market expansion are common competitive strategies. Furthermore, companies are engaging in training-based marketing by establishing surgeon training programs in PCNL to drive product adoption, improve procedural outcomes, and strengthen brand loyalty in the urology market.
 

Percutaneous Nephrolithotomy Market Companies

A few of the prominent players operating in the percutaneous nephrolithotomy industry include:

• ADVIN
• B. BRAUN
• Becton, Dickinson and Company
• Boston Scientific
• Coloplast
• COOK MEDICAL
• Dornier MedTech
• ELMED
• EMS ELECTRO MEDICAL SYSTEMS
• KARL STORZ
• OLYMPUS
• PolyDiagnost
• Richard Wolf 
• Teleflex
   
• OLYMPUS

Olympus offers advanced imaging-integrated nephroscopes and endoscopic visualization systems that enhance surgical precision during PCNL. Its strong global service network and reliable product quality drive high customer retention among hospitals and urology centers.
 

• KARL STORZ

Karl Storz is known for its durable, precision-crafted nephroscopes and complete mini-PCNL instrument sets designed for reduced tract size and superior clinical control. The brand enjoys strong surgeon preference due to ergonomic design and consistent optical performance.
 

• Boston Scientific

Boston Scientific provides a comprehensive kidney stone management portfolio, including laser lithotripsy, stone retrieval devices, guidewires, and access tools compatible with PCNL workflows. Its strong clinical support programs and procedural training initiatives help accelerate adoption among urologists.
 

Percutaneous Nephrolithotomy Industry News:

• In February 2025, Ambu announced the expansion of its European regulatory clearance (CE mark) for the Ambu aScope 5 Cysto HD solution. This additional clearance enabled Ambu’s existing HD technology to function as a single-use flexible cysto-nephroscopy solution, addressing a new niche procedure within urology. This development is expected to support growth in the PCNL market by promoting infection-free procedures, reducing sterilization costs, and accelerating the adoption of single-use nephroscopy solutions in hospitals and surgery centers.
   

The percutaneous nephrolithotomy market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Nephroscopes
  • Rigid
  • Flexible
• Lithotripsy systems
• Access systems
• Other product types

Market, By Procedure Type

• Standard PCNL
• Mini-PCNL
• Micro-PCNL

Market, By Patient

• Adult
• Pediatric

Market, By End Use

• Hospitals
• Ambulatory surgery centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE